Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dean

Showing results (391-400 of 401) with videos related to

Pageof 41
Sort By:
The Lancet. Oncology|February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyMichael Wang, Wojciech Jurczak, Marek Trneny, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Blood Advances|June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studiesSteven E Coutre, John C Byrd, Peter Hillmen, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trialLi-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Nature|April 9, 2025
Transforming ceria into 2D clusters enhances catalytic activityKonstantin Khivantsev, Hien Pham, Mark H Engelhard, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|May 12, 2017
Critical care admission of South African (SA) surgical patients: Results of the SA Surgical Outcomes StudyDavid Lee Skinner, Kim De Vasconcellos, Robert Wise, et al.
Pageof 41

Showing results (391-400 of 401) with videos related to

Sort By:
Pageof 41
The Lancet. Oncology|February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyMichael Wang, Wojciech Jurczak, Marek Trneny, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Blood Advances|June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studiesSteven E Coutre, John C Byrd, Peter Hillmen, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trialLi-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Nature|April 9, 2025
Transforming ceria into 2D clusters enhances catalytic activityKonstantin Khivantsev, Hien Pham, Mark H Engelhard, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|May 12, 2017
Critical care admission of South African (SA) surgical patients: Results of the SA Surgical Outcomes StudyDavid Lee Skinner, Kim De Vasconcellos, Robert Wise, et al.
Pageof 41